Payment overview · 2025
General Payments
$100.42
5 reported records · 4 companies
Healthcare provider profile · identity verified
John West, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MC COOK, NE · NPI 1063485290
Verified facts
What the public records show
CMS Open Payments records show John West, M.D. received $100.42 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.37 | 34.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.85 | 29.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.50 | 21.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $14.70 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $100.42 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 41 |
| Lisinopril | Lisinopril | 254 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 28 |
| Eliquis | Apixaban | 149 | 17 |
| Metformin Hcl Er | Metformin Hcl | 149 | 30 |
| Potassium Chloride | Potassium Chloride | 147 | 22 |
| Losartan Potassium | Losartan Potassium | 133 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 21 |
| Simvastatin | Simvastatin | 129 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 22 |
| Omeprazole | Omeprazole | 121 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 29 |
| Trazodone Hcl | Trazodone Hcl | 119 | 22 |
| Glimepiride | Glimepiride | 107 | 15 |
| Furosemide | Furosemide | 104 | 19 |
| Celecoxib | Celecoxib | 102 | 29 |
| Carvedilol | Carvedilol | 101 | 17 |
| Metformin Hcl | Metformin Hcl | 99 | 15 |
| Sertraline Hcl | Sertraline Hcl | 96 | 16 |
| Warfarin Sodium | Warfarin Sodium | 96 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 22 |
| Gabapentin | Gabapentin | 80 | 13 |
| Famotidine | Famotidine | 76 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | suppressed |
| Januvia | Sitagliptin Phosphate | 70 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 66 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 13 |
| Jardiance | Empagliflozin | 63 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | suppressed |
| Clonazepam | Clonazepam | 60 | suppressed |
| Ozempic | Semaglutide | 60 | suppressed |
| Meloxicam | Meloxicam | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Allopurinol | Allopurinol | 45 | 12 |
| Valsartan | Valsartan | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Prednisone | Prednisone | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100.42 · 5 records | PFIZER INC. | ABRYSVO, BREZTRI, COMIRNATY, EVKEEZA, PREVNAR 20, WATCHMAN Access System | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error